TMCnet News

Research and Markets: Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating
[May 26, 2014]

Research and Markets: Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/v8dx35/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering.

One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis.

Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders.

Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologcs for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics.



Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders.

Key vendors dominating this space include


  • AbbVie Inc.
  • Galderma S.A.
  • Johnson & Johnson Ltd.
  • Novartis AG
  • Stiefel Laboratories Inc.
  • Valeant Pharmaceuticals International Inc.

Other vendors mentioned in the report are

  • Actavis plc
  • Allergan Inc.
  • Almirall SA
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Celgene Corp.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Genentech Inc.
  • Incyte Corp.
  • Isotechnika Inc.
  • LEO Pharma A/S
  • Merck & Co. Inc.
  • Mylan Pharmaceuticals Inc.
  • Pfizer Inc.
  • UCB SA.

Key questions answered in this report:

  • What will the market size and growth rate be in 2018?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by key vendors?
  • What are the strengths and weaknesses of each of these key vendors?

For more information visit http://www.researchandmarkets.com/research/v8dx35/global


[ Back To TMCnet.com's Homepage ]